Skip to main content

Advertisement

SpringerLink
Log in

Improvement in hereditary hemorrhagic telangiectasia after treatment with the multi-kinase inhibitor Sunitinib

  • Letter to the Editor
  • Published:
Annals of Hematology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Dupuis-Girod S, Bailly S, Plauchu H (2010) Hereditary hemorrhagic telangiectasia: from molecular biology to patient care. J Thromb Haemost 8(7):1447–1456

    Article  CAS  PubMed  Google Scholar 

  2. 2 National Cancer Institute. Common Terminology Criteria for Adverse Events v 4.03 (CTCAE). Available at: http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf. Accessed 17 Mar 2016

  3. Hoag JB, Terry P, Mitchell S et al (2010) An epistaxis severity score forhereditary hemorrhagic telangiectasia. Laryngoscope 120(4):838–843

    Article  PubMed  Google Scholar 

  4. Robinson K, Gatehouse S, Browning GG (1996) Measuring patient benefit from otorhinolaryngological surgery and therapy. Ann Otol Rhinol Laryngol 105(6):415–422

    Article  CAS  PubMed  Google Scholar 

  5. Mendel DB, Laird AD, Xin X et al (2003) In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and plateletderived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9:327–937

    CAS  PubMed  Google Scholar 

  6. Kanellopoulou T, Alexopoulou A (2013) Bevacizumab in the treatment of hereditary hemorrhagic telangiectasia. Expert Opin Biol Ther 13(9):1315–1323

    Article  CAS  PubMed  Google Scholar 

  7. Geisthoff UW, Nguyen HL, Hess D (2014) Improvement in hereditary hemorrhagic telangiectasia after treatment with the phosphoinositide 3-kinase inhibitor BKM120. Ann Hematol 93(4):703–704

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

The authors would like to thank the patient and Dr. med. Marcus Koester for helping us with the follow-up of the patient and for providing information and discussion on Sunitinib.

Funding

This research received no specific grant from any funding agency, commercial, or not-for-profit sectors.

Author information

Authors and Affiliations

  1. Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital Essen, University Duisburg-Essen, Hufelandstrasse 55, 45147, Essen, Germany

    Freya Droege, Kruthika Thangavelu, Stephan Lang & Urban Geisthoff

Authors
  1. Freya Droege
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kruthika Thangavelu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Stephan Lang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Urban Geisthoff
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Freya Droege.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This article does not contain any studies with animals performed by any of the authors. The study was approved by the Ethics Committee of the University Duisburg-Essen.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Droege, F., Thangavelu, K., Lang, S. et al. Improvement in hereditary hemorrhagic telangiectasia after treatment with the multi-kinase inhibitor Sunitinib. Ann Hematol 95, 2077–2078 (2016). https://doi.org/10.1007/s00277-016-2796-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-016-2796-6

Keywords

Search

Navigation